Phase III RHAPSODY trial of rilonacept meets endpoints in pericarditis.- Kiniksa Pharma
Kiniksa Pharmaceuticals announced that the Phase III RHAPSODY trial showed that rilonacept achieved its primary and all major secondary efficacy endpoints in patients with recurrent pericarditis. Results show… read more.